Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Current Drug Targets
Title:Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Volume: 16 Issue: 3
Author(s): Mohammad Bashashati, Hamid R. Habibi, Ali Keshavarzian, Max Schmulson and Keith A. Sharkey
Affiliation:
Keywords: Coronary artery disease, gastrointestinal inflammation, inflammatory bowel disease, microbiota, trimethylamine N-oxide.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting gastrointestinal (GI) disorders of unknown etiology. IBD patients commonly exhibit extra-intestinal manifestations and complications of an inflammatory nature, presenting with disorders such as ankylosing spondylitis, uveitis and vasculitis. Although the metabolic syndrome is less prevalent in patients with IBD, they are at an increased risk for atherosclerosis and cardiovascular events. Considerable evidence supports the role of GI microbiota in the development of IBD. Recent studies have also shown a significant interaction between the metabolites of gut microbiota and the development of cardiovascular disease. Here we hypothesize that dysbiosis and/or abnormalities in the function of the intestinal microbiota promote cardiovascular disease in IBD patients, explaining the increased risk of cardiovascular events in these patients.
Export Options
About this article
Cite this article as:
Bashashati Mohammad, Habibi R. Hamid, Keshavarzian Ali, Schmulson Max and A. Sharkey Keith, Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?, Current Drug Targets 2015; 16 (3) . https://dx.doi.org/10.2174/1389450116666150120104012
DOI https://dx.doi.org/10.2174/1389450116666150120104012 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Strategies in the Management of Children and Adolescents with Proliferative Lupus Nephritis
Current Rheumatology Reviews Gastrointestinal Hemorrhage is Associated with Mortality after Acute Ischemic Stroke
Current Neurovascular Research Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Haptoglobin Phenotype Correlates with the Extent of Cerebral Deep White Matter Lesions in Hypertensive Patients
Current Neurovascular Research Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert
Medicinal Chemistry MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases
Current Genomics Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry The Optimal Treatment of Thyroid Gland Function Disturbances During Pregnancy
Current Pharmaceutical Biotechnology Complement System in SLE as a Target for Antibodies
Current Rheumatology Reviews Nitric Oxide and Cyclic GMP Signaling Pathway as a Focus for Drug Development
Current Medicinal Chemistry Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Application of Transcranial Color-Coded Duplex Sonography in Stroke Diagnosis
Current Medical Imaging Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms
Current Medicinal Chemistry Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design